loading
Schlusskurs vom Vortag:
$8.97
Offen:
$9.04
24-Stunden-Volumen:
49,807
Relative Volume:
0.06
Marktkapitalisierung:
$478.78M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-9.5957
EPS:
-0.94
Netto-Cashflow:
$-33.83M
1W Leistung:
-0.98%
1M Leistung:
+4.70%
6M Leistung:
+93.54%
1J Leistung:
+98.26%
1-Tages-Spanne:
Value
$8.90
$9.15
1-Wochen-Bereich:
Value
$8.32
$9.27
52-Wochen-Spanne:
Value
$4.20
$9.27

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name
Firmenname
Zevra Therapeutics Inc
Name
Telefon
(321) 939-3416
Name
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Name
Mitarbeiter
69
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
ZVRA's Discussions on Twitter

Vergleichen Sie ZVRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ZVRA 9.005 478.78M 27.46M -46.05M -33.83M -0.94
VRTX 447.18 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.71 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.39 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.84 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.36 24.49B 3.30B -501.07M 1.03B 11.54

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-03-17 Eingeleitet Maxim Group Buy

Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten

pulisher
07:52 AM

HC Wainwright Expects Lower Earnings for Zevra Therapeutics - MarketBeat

07:52 AM
pulisher
Nov 20, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Guggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy Recommendation - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Zevra Therapeutics (STU:1GDA) Enterprise Value : €424.12 Mil (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 18, 2024
pulisher
Nov 18, 2024

ZVRA FY2024 EPS Forecast Decreased by Cantor Fitzgerald - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

What is William Blair's Forecast for ZVRA FY2024 Earnings? - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report - Yahoo Finance

Nov 16, 2024
pulisher
Nov 15, 2024

Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study - Ehlers-Danlos News

Nov 15, 2024
pulisher
Nov 15, 2024

Simplify Asset Management Inc. Invests $833,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

What is William Blair's Estimate for ZVRA FY2026 Earnings? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St

Nov 15, 2024
pulisher
Nov 15, 2024

Roth Capital Forecasts Lower Earnings for Zevra Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Decline in Short Interest - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: Zevra Therapeutics reports Q3 financial results - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Given New $23.00 Price Target at Canaccord Genuity Group - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Q4 Earnings Forecast for ZVRA Issued By Roth Capital - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

Zevra Therapeutics’ Transformative Third Quarter 2024 - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Zevra Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 12, 2024
pulisher
Nov 12, 2024

Zevra Therapeutics earnings missed by $0.28, revenue fell short of estimates - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... By GuruFocus - Investing.com Canada

Nov 12, 2024
pulisher
Nov 11, 2024

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Kn - GuruFocus.com

Nov 11, 2024
pulisher
Nov 11, 2024

Zevra Therapeutics Validates Key Clinical Scale for Niemann-Pick Disease Treatment Study | ZVRA Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 08, 2024

International Assets Investment Management LLC Raises Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

(ZVRA) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 07, 2024
pulisher
Nov 07, 2024

ZVRA stock touches 52-week high at $8.96 amid market rally - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $20.83 Average PT from Analysts - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Zevra Therapeutics CEO to Present at Guggenheim Healthcare Conference | ZVRA Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Zevra Therapeutics Inc - GuruFocus.com

Nov 05, 2024
pulisher
Oct 31, 2024

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - The Manila Times

Oct 31, 2024
pulisher
Oct 29, 2024

Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline - Yahoo Finance

Oct 29, 2024
pulisher
Oct 28, 2024

How To Trade (ZVRA) - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 24, 2024

Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury

Oct 24, 2024
pulisher
Oct 22, 2024

Will Zevra Gallop Or Saunter In Q3? - RTTNews

Oct 22, 2024
pulisher
Oct 17, 2024

Objective long/short (ZVRA) Report - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 17, 2024

Sanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Zevra therapeutics director Corey Watton buys $3,957 in stock - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Zevra therapeutics director Corey Watton buys $3,957 in stock By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 14, 2024

Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN

Oct 14, 2024

Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Zevra Therapeutics Inc-Aktie (ZVRA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Clifton R. LaDuane
CFO & Treasurer
Jul 17 '24
Buy
6.77
2,000
13,540
18,469
Anderson Thomas
Director
Jul 16 '24
Buy
6.81
10,000
68,065
20,000
Bode John B
Director
Jul 12 '24
Buy
5.87
10,000
58,661
30,000
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):